Abstract 278P
Background
Tamoxifen is effective for the adjuvant treatment of primary breast cancer, but increases the risk for venous thromboembolism. Tamoxifen decreases anticoagulant proteins, including antithrombin (AT), protein C (PC) and tissue factor pathway inhibitor, and increases thrombin generation (TG). However, the relation between levels of both tamoxifen and its active metabolite endoxifen and coagulation is unknown. To gain insight in the prothrombotic effects of tamoxifen and to guide safe dose-escalation, which may be performed in case of sub-therapeutic endoxifen levels, we studied the association between tamoxifen and endoxifen levels and various clotting proteins.
Methods
Tamoxifen and endoxifen levels were measured in 148 patients from the prospective TOTAM study (NL6918) after 3 months (m) and 6m of tamoxifen treatment. Plasma levels of the anticoagulants AT and PC, the procoagulant tissue factor (TF), and TG parameters were determined at both timepoints if samples were available (n=65-138 per analysis). Levels of clotting proteins and TG parameters were compared between: 1) quartiles of tamoxifen and endoxifen levels with ANOVA or Kruskall-Wallis with Dunnett’s test, and 2) 3m and 6m of treatment in patients without dose adjustments with paired sample t-tests or Wilcoxon signed rank tests.
Results
After 3m of tamoxifen, levels of AT, PC, TF and TG parameters were not associated with tamoxifen nor endoxifen levels. At 6m, median TF levels were lower in patients in the 3rd (45 [range: 101] pg/mL), and 4th (50 [90] pg/mL) endoxifen quartiles compared to the 1st (lowest) quartile (70 [143] pg/mL) (adjusted P of 0.024 and 0.012, respectively), but no differences in anticoagulants or TG were observed. An increase in both median TF levels (3m: 46 [94], 6m: 54 [143] pg/mL, P<0.001) and TG parameters was observed at the 6m treatment period, while the AT and PC levels remained stable.
Conclusions
Our results indicate that higher tamoxifen and endoxifen levels are not associated with increased coagulation system activation, suggesting that both tamoxifen dose-escalation and high endoxifen levels do not have an additional prothrombotic effect. The time-dependent effect of tamoxifen on coagulation warrants further study.
Clinical trial identification
NL6918.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M.J.H.A. Kruip: Financial Interests, Institutional, Research Grant, Unrestricted research grant, payment to institute, unrelated to this research: Sobi; Financial Interests, Institutional, Speaker, Consultant, Advisor, Speakers fee, payment to institute, unrelated to this research: Sobi, Roche, BMS. R.H. Mathijssen: Financial Interests, Institutional, Research Grant, Investigator-initiated research: Astellas, Bayer, Cristal Therapeutics, Pfizer, Roche, Sanofi, Servier, Boehringer-Ingelheim, Novartis; Financial Interests, Institutional, Coordinating PI: Pamgene. All other authors have declared no conflicts of interest.
Resources from the same session
263P - Efficacy and safety of neoadjuvant chemotherapy combination with pembrolizumab in triple-negative breast cancer: Real-world data
Presenter: Layal Rached
Session: Poster session 02
264P - Tumor-infiltrating lymphocytes (TILs) for prediction of response to platinum-based neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC): Final analysis
Presenter: Sheyda Abdullaeva
Session: Poster session 02
265P - Effect of HER2-low-positive status on neoadjuvant chemotherapy and survival outcome of breast cancer: A 10-year dual-center retrospective study
Presenter: Yijun Li
Session: Poster session 02
266P - Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: A systematic review and meta-analysis
Presenter: Francesca Schipilliti
Session: Poster session 02
267P - Pathological complete response after neoadjuvant chemotherapy plus pertuzumab and trastuzumab for HER2+ early breast cancer: Real-world data from NeoPowER study
Presenter: Fabio Canino
Session: Poster session 02
268P - Evaluating the efficacy of adjuvant capecitabine in triple-negative breast cancer patients with residual disease: A real-world evidence study
Presenter: Min Jeong Kim
Session: Poster session 02
269P - Achieving treatment goals in elderly breast cancer patients with neoadjuvant chemotherapy: A remarkable insight
Presenter: Eda Caliskan Yildirim
Session: Poster session 02
270P - Influence of neoadjuvant chemotherapy-induced short-term amenorrhea on pathologic response and treatment outcome in ER+HER2- breast cancer
Presenter: Seung Eun Lee
Session: Poster session 02
271P - First clinical demonstration of the predictive value of tissue nanomechanical signature in breast cancer patients in neoadjuvant therapy setting
Presenter: Sara Nizzero
Session: Poster session 02